Today: 29 April 2026
Browse Category

Stock Market 24 December 2025

Micron Technology (MU) Stock Hits Fresh Records on Dec. 24, 2025: AI Memory Crunch, Blowout Guidance, and Wall Street’s Latest Forecasts

Micron Technology (MU) Stock Hits Fresh Records on Dec. 24, 2025: AI Memory Crunch, Blowout Guidance, and Wall Street’s Latest Forecasts

Micron Technology shares hit a record high near $289 during the shortened Christmas Eve session after reporting Q1 2026 revenue of $13.64 billion and strong guidance for Q2. The company projected $18.7 billion in revenue and 68% gross margin for next quarter, citing tight memory supply driven by AI data center demand. Analysts issued upgrades, with Rosenblatt setting a $500 price target.
24 December 2025
···
Marvell Technology (MRVL) Stock News Today: Celestial AI Deal, Earnings Momentum, and Wall Street Forecasts (Dec. 24, 2025)

Marvell Technology (MRVL) Stock News Today: Celestial AI Deal, Earnings Momentum, and Wall Street Forecasts (Dec. 24, 2025)

Marvell Technology shares closed at $86.40 on December 24, 2025, down 1.46% after leading Nasdaq gains the previous session. The stock has traded between $47.09 and $127.48 over the past year. Q3 fiscal 2026 revenue hit a record $2.075 billion, with data center sales making up 73% of the total. Investors remain focused on Marvell’s AI connectivity strategy after its Celestial AI acquisition.
24 December 2025
···
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer shares traded near $25 on Dec. 24, 2025, valuing the company at about $142 billion amid thin holiday trading. The company’s 2026 guidance, released Dec. 16, projects revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with growth not expected to rebound until later in the decade. Investors remain focused on drug pricing risks, pipeline progress, and looming patent expirations.
24 December 2025
···
Goldman Sachs (GS) Stock Today: Shares Hover Near 52-Week High as 2026 Earnings, M&A Momentum, and Analyst Targets Collide

Goldman Sachs (GS) Stock Today: Shares Hover Near 52-Week High as 2026 Earnings, M&A Momentum, and Analyst Targets Collide

Goldman Sachs traded near $909 in a shortened Christmas Eve session, up 0.8% and within 1% of its 52-week high. The stock has surged nearly 60% in 2025, driven by strong investment banking and trading revenues. Goldman announced plans to invest about ¥800 billion ($5.1 billion) in Japan’s corporate deals market over the next decade.
24 December 2025
·
Lam Research (LRCX) Stock News on Dec. 24, 2025: CEO Share Sale, Analyst Targets, and the AI-Driven Wafer-Fab Equipment Outlook

Lam Research (LRCX) Stock News on Dec. 24, 2025: CEO Share Sale, Analyst Targets, and the AI-Driven Wafer-Fab Equipment Outlook

Lam Research traded near $177 in midday Dec. 24, approaching record highs after CEO Timothy Archer disclosed the sale of 163,300 shares for about $26.8 million under a 10b5-1 plan. The stock is up from its Dec. 23 close of $175.16. Trading volume was lighter ahead of the 1 p.m. ET early market close for Christmas Eve.
24 December 2025
··
Zeta Global (ZETA) Stock Surges on Dec. 24, 2025: Holiday Trading Spike, Analyst Targets, and the Marigold Growth Story

Zeta Global (ZETA) Stock Surges on Dec. 24, 2025: Holiday Trading Spike, Analyst Targets, and the Marigold Growth Story

Zeta Global shares rose 4.36% to near $19.15 by midday December 24, 2025, in a thinly traded, early-closing session. The move followed a gap-up open and heavy options activity, with investors reacting to the company’s raised 2025–2026 outlook after its $325 million Marigold enterprise acquisition. Major indexes hovered near record highs. No new company headlines were issued during the session.
24 December 2025
··
American Airlines Group (NASDAQ: AAL) Stock News Today: Christmas Eve Trading, Analyst Forecasts, and the 2026 Outlook (Dec. 24, 2025)

American Airlines Group (NASDAQ: AAL) Stock News Today: Christmas Eve Trading, Analyst Forecasts, and the 2026 Outlook (Dec. 24, 2025)

American Airlines shares closed at $15.68 on Dec. 24, down 0.48% in light holiday trading after fluctuating between $15.49 and $15.74. The session followed a volatile week and came as U.S. holiday air travel hit record highs, with TSA preparing for 44.3 million travelers through early January. American recently stopped awarding miles on basic economy fares bought after Dec. 17.
24 December 2025
·
BitMine Immersion Technologies (BMNR) Stock: Latest News, Analyst Forecasts, and What to Watch on Dec. 24, 2025

BitMine Immersion Technologies (BMNR) Stock: Latest News, Analyst Forecasts, and What to Watch on Dec. 24, 2025

BitMine Immersion Technologies reported holding over 4 million ETH as of Dec. 21, 2025, with total crypto and cash assets valued at $13.2 billion. BMNR shares traded near $29 on Dec. 24, within a 52-week range of $3.20 to $161.00. Strong Tower Advisory Services disclosed a new 276,412-share position in Q3 filings. The company’s ETH holdings represent 3.37% of total ETH supply.
24 December 2025
··
Bank of America Stock (BAC) Today: Christmas Eve Trading, Fresh News, Analyst Forecasts and the 2026 Outlook (Dec. 24, 2025)

Bank of America Stock (BAC) Today: Christmas Eve Trading, Fresh News, Analyst Forecasts and the 2026 Outlook (Dec. 24, 2025)

Bank of America shares traded near $56.45 on Dec. 24, up 0.85% in a shortened holiday session, with the S&P 500 hitting a record intraday high. The Federal Reserve cut rates by 25 basis points earlier in December, lowering the target range to 3.50%–3.75%. Investors watched for thin trading and sharp moves as markets closed early. Rate expectations and sector rotation into financials shaped trading.
24 December 2025
·
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

China’s NMPA approved Zai Lab’s COBENFY for adult schizophrenia on Dec. 23, triggering a surge in Zai Lab shares. The U.S. ADR traded around $18.54 intraday, while Hong Kong shares closed at HK$14.48, up 6.24%. COBENFY is the first M1/M4 muscarinic receptor therapy for schizophrenia approved in China. Zai Lab holds exclusive commercialization rights in Greater China.
24 December 2025
···
Salesforce (CRM) Stock News Today: Agentforce Momentum, AI Reliability Questions, and Updated Wall Street Forecasts (Dec. 24, 2025)

Salesforce (CRM) Stock News Today: Agentforce Momentum, AI Reliability Questions, and Updated Wall Street Forecasts (Dec. 24, 2025)

Salesforce shares traded near $266 at midday Dec. 24, up slightly, but remain down about 21% for 2025 after a volatile year. Q3 FY2026 results showed revenue of $10.3 billion, up 9% year-over-year, and a non-GAAP operating margin of 35.5%. The company raised its full-year revenue guidance to $41.45–$41.55 billion. Investors are watching adoption of Agentforce and Data 360 amid debate over AI reliability.
24 December 2025
··
Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences shares traded around $18.1–$18.5 on December 24, 2025, holding gains after positive WVE-007 obesity data and a recent capital raise. No new company news crossed the wire, but analysts raised fair value targets following the Phase 1 results showing reduced visceral fat and increased lean mass. At least one after-hours trade printed below the regular close amid thin holiday volume.
24 December 2025
··
Intel Stock INTC Slips as Nvidia Pauses 18A Test: Latest News, Forecasts, and What Matters Next

Intel Stock INTC Slips as Nvidia Pauses 18A Test: Latest News, Forecasts, and What Matters Next

Intel shares fell about 1% to $35.97 on December 24 after reports that Nvidia halted testing of Intel’s 18A chip manufacturing process. Trading was light in a shortened Christmas Eve session. Intel said its 18A technology is progressing and highlighted ongoing interest in its next-generation 14A process. The U.S. government recently announced an $8.9 billion equity investment in Intel.
24 December 2025
·
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics shares jumped about 15% to over $40 in early trading on Dec. 24, 2025, hitting new highs during a holiday-shortened session. The surge followed investor anticipation of an FDA decision on FILSPARI for FSGS, expected by Jan. 13, 2026. No company news was released that day. The FDA previously waived an advisory committee review for the application.
24 December 2025
·
Nike Stock (NKE) Jumps on Tim Cook’s $3M Share Buy as Turnaround Pressures Mount: News, Forecasts and Analysis for Dec. 24, 2025

Nike Stock (NKE) Jumps on Tim Cook’s $3M Share Buy as Turnaround Pressures Mount: News, Forecasts and Analysis for Dec. 24, 2025

Nike shares jumped about 5% to $60 in a shortened Christmas Eve session after filings showed Apple CEO Tim Cook bought 50,000 shares, nearly doubling his stake. The $3 million open-market purchase, disclosed Wednesday, came after Nike stock had dropped 13% following disappointing guidance and margin concerns. Another director, Robert Swan, also bought shares.
24 December 2025
··
Home Depot Stock (HD) News Today, Dec. 24, 2025: Price Action, Analyst Forecasts, and What Investors Are Watching

Home Depot Stock (HD) News Today, Dec. 24, 2025: Price Action, Analyst Forecasts, and What Investors Are Watching

Home Depot shares rose 0.7% to $347.51 in light trading during a shortened Christmas Eve session. Wall Street analysts maintained a “Buy” consensus, but earnings estimate revisions turned slightly negative. The Schall Law Firm announced a new fraud investigation tied to Home Depot’s Q3 2025 results. The S&P 500 hit a record intraday high as broader market sentiment improved.
24 December 2025
·
Procter & Gamble (PG) Stock Today: Analyst Upgrades, Tariff Pressures, and a CEO Change Set the Tone for 2026

Procter & Gamble (PG) Stock Today: Analyst Upgrades, Tariff Pressures, and a CEO Change Set the Tone for 2026

Procter & Gamble shares traded near $144.70 on December 24, rebounding slightly after hitting a yearly low of $138.14 earlier in December. The stock is down about 12% year-to-date. A CEO transition is set for January 1, with Shailesh Jejurikar replacing Jon Moeller. The company plans to cut 7,000 non-manufacturing jobs and exit some product categories.
24 December 2025
·
Polestar Stock (PSNY) Surges on Fresh Funding: Latest News, Analyst Forecasts, and What Investors Are Watching (Dec. 24, 2025)

Polestar Stock (PSNY) Surges on Fresh Funding: Latest News, Analyst Forecasts, and What Investors Are Watching (Dec. 24, 2025)

Polestar shares surged about 13% to $17.09 on December 24, 2025, after announcing a $300 million equity investment from BBVA and Natixis, plus a $300 million debt-to-equity conversion with Geely. Trading volume topped 200,000 shares. The moves aim to boost liquidity and address debt concerns as the company faces EV market pressures.
24 December 2025
··
Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck shares hit a 12-month high near $106 on December 24, 2025, capping a 30% rally over three months. The surge follows a Trump administration deal requiring Merck to cut prices on drugs like Januvia for Medicaid and direct-to-consumer sales. Analysts cite optimism about Merck’s growth beyond Keytruda’s patent expiration and progress on new drugs.
24 December 2025
··
1 … 840 841 842 843 844 … 1,398

Stock Market Today

  • AbbVie (ABBV) Valuation Analysis: Recent Softness vs Long-Term Gains
    April 28, 2026, 11:57 PM EDT. AbbVie's recent stock performance shows a 5.59% gain over 30 days but a 13.79% decline year-to-date, contrasting with a 109.36% total shareholder return over five years. Despite share price weakness, analysts estimate a fair value near $249, suggesting the stock may be undervalued against the current price of $197.69. AbbVie's diversified pipeline and specialty pharma focus support premium pricing and margin protection. However, risks include government pricing pressures and competitive challenges to key drugs. The current price-to-earnings ratio is 83.5x, significantly above the biotech average, indicating valuation risks if investor sentiment shifts.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop